漢達生技

漢達生技 https://validator.w3.org/feed/docs/rss2.html Material Information- The Company has been required by TPEx to announce the financial data according 重大訊息-本公司因近期股價價格異常，應櫃買中心要求公布相關資訊，俾便投資人暸解 Material Information- Announcement of the Company’s Ex-Dividend Record Date and Related Matters 重大訊息-公告本公司訂定除息基準日相關事宜 Material Information- Announcement of the 2026 Annual Shareholders’Meeting Approved the Proposal to release the Non-Competition Restrictions on Directors 重大訊息-公告本公司115年股東常會通過解除董事競業禁止之限制 Material Information- Announcement of the Important Resolutions of the Company’s 2026 Annual Shareholders’ Meeting 重大訊息-公告本公司115年股東常會重要決議事項 Material Information- Announcement of the Completion of the Company’s Treasury Share Buyback 重大訊息-公告本公司買回庫藏股執行完畢 Material Information- Announcement that the cumulative number of treasury shares repurchased by the Company has reached 2% of the total issued shares 重大訊息-公告本公司買回庫藏股數量累積達公司已發行股份總額百分之二事宜 Material Information- Announcement of the Completion of Registration for the Cancellation of Restricted Employee Shares Issued by the Company 重大訊息-公告本公司限制員工權利新股註銷完成變更登記事宜 Major Internal Policies 重要公司規章 Financials 財務資訊 Group Structure 集團架構 Material Information- Clarification of Media Report 重大訊息-澄清媒體報導 Material Information- Announcement of the Board’s Resolution to release the non-competition restriction on managerial officers Material Information- Announcement of the Board’s Resolution to redeem and cancel restricted employee shares for a capital reduction Material Information- Announcement of the Board of Directors approved the consolidated financial statements for 2026 Q1. Material Information- Announcement of the expected date of the Board Meeting to approve 2026 Q1 Financial Report on May 7, 2026 Stakeholder 利害關係人專區 Company Profile 公司基本資料重大訊息-本公司董事會通過解除經理人競業禁止之限制案 Management Team 重大訊息-公告本公司董事會決議辦理限制員工權利新股收回註銷減資事宜重大訊息-公告本公司董事會通過115年第一季合併財務報告重大訊息-公告本公司115年第一季財務報告董事會預計召開日期為115年5月7日獨立董事與內部稽核主管及會計師之溝通情形經營團隊 Company Overview 公司簡介 Material Information- Announcement of the Board’s Resolution to Repurchase Treasury Shares Material Information- Announcement of the Completion of the Company’s Treasury Share Buyback Material Information- Announces on behalf of the subsidiary Handa Oncology, LLC, regarding the 505(b)(2) new formulation drug HND-039 citizen petition to the FDA examination 重大訊息-公告本公司董事會決議買回庫藏股事宜重大訊息-公告本公司買回庫藏股執行完畢重大訊息-代子公司Handa Oncology, LLC公告505(b)(2)新藥HND-039美國FDA藥品審查訴願案法說會資訊 Material Information- The Company was invited to attend the in-person and virtual institutional investor conference hosted by First Securities 重大訊息-本公司受邀參加第一金證券舉辦之實體暨線上法人說明會 Material Information- Correction to the Material Information announced on March 12, 2026: Announcement of the newly appointed Chief Innovation Officer 首頁